Bayer joined the Sensyne Health alliance to accelerate the development of new drugs

Health and Bayer announced that Bayer will be Sensyne Health's preferred pharmaceutical partner to jointly develop country-relevant patient data capabilities.Microsoft, EY, JPMorgan Chase and Peel Hunt have joined the alliance. Under the terms of the agreement, Bayer will work with Sensyne Health and consortium members to develop proposals to expand Sensyne Health's current network of strategic research protocols with NHS Trusts, aimed at accelerating the discovery and development of new drugs and using clinical artificial intelligence to analyze anonymous patient data through improved patient care.Sensyne Health and its alliance of experts have the necessary capabilities for clinical AI, computing, data analysis, system integration, business planning, investment banking, and have added Bayer's relevant pharmaceutical research and development expertise and capabilities.“ Access to anonymous nationally relevant patient data heralds a new era of drug discovery and development," said Bayer Innovation board member Kemal Malik. Importantly, this will allow the steps to prevent them from moving along that path. Bayer is pleased to be able to leverage its expertise to develop this capability. " in keeping with Sensyne Health's ethical framework and business model, the NHS remains the controller of NHS patient data and no data is sold or transferred to third parties.The company acts as a "docking station" to analyze anonymous patient data under strict ethical control on behalf of its business partners. (China Pharmaceutical 123 Network)